A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions

Advanced Solid TumorLymphoma

Interventions

DRUG

DS-3078a

DS-3078a will be administered as oral capsules once daily and will be supplied in 5, 20, 50, and 150 mg capsules.

Trial Locations (1)

South Texas Accelerated Research Therapeutics, San Antonio